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RISPERIDONE LONG ACTING INJECTION (RLAI) IN THE
TREATMENT OF EARLY VERSUS LATE DIAGNOSIS PATIENTS
WITH SCHIZOPHRENIA: INTERIM RESULTS FROM
OBSERVATIONAL STUDIES CONDUCTED IN SPAIN,
AUSTRALIA AND BELGIUM
Olivares JM1, Lambert TJR2, Peuskens J3, Caleo S4, Povey M5, Lam A6
1Servicio de Psiquiatria Hospital,Vigo, Spain, 2The University of
Melbourne, Melbourne,Victoria, Australia, 3Universitair Psychiatrisch
Centrum, KUL Leuven, Leuven, Belgium, 4Janssen Pharmaceutica N.V,
Beerse, Belgium, 5SGS Life Science Services Belgium, Wavre, Belgium,
6Johnson and Johnson Pharmaceutical Services,Toronto, ON, Canada
OBJECTIVES: To compare 12-month psychiatric-related hospi-
talization pre and post-RLAI therapy and clinical outcomes in
early (<5-years) versus late (°Y´5-years) diagnosis outpatients
with schizophrenia from e-STAR in Spain (SP), Australia (AU),
and Belgium (BE). METHODS: E-STAR is a secure, web-based,
international, long-term observational study of patients with
schizophrenia who commence RLAI treatment. Data are col-
lected both retrospectively and prospectively and include hospi-
talisations and clinical outcomes that were evaluated using the
Clinical Global Impression Severity Scale (CGI-S) and Global
Assessment of Functioning Scale (GAF). RESULTS: Overall, 714
patients (SP = 393, AU = 249, BE = 72) were included. Twenty-
two percent were classiﬁed as early diagnosis. Average time since
diagnosis was 2 and 15.9 years in the early and late diagnosis
group, respectively. Patients in the early diagnosis group were
signiﬁcantly younger than those in the late diagnosis group (32.2
vs. 41.7, p < 0.001). Both groups experienced a signiﬁcant
decrease in the number of hospitalizations per patient in the 12-
month post versus the 12-month pre-RLAI period (early = 0.77
to 0.36, p < 0.001; late = 0.54 to 0.43, p = 0.004). Reduction in
hospitalization rates per patient from the pre and post-RLAI
period was signiﬁcantly greater in the early diagnosis group
(early = −0.4, late = −0.11, p = 0.006). The average length of
stay (in days) decreased for both groups but it was only statisti-
cally signiﬁcant in the early diagnosis group (early = 21.2 to 12.4,
p = 0.041; late = 15.6 to 13.6, p = 0.40). Both groups experi-
enced signiﬁcant improvements in GAF and CGI-S scores.
However, the early diagnosis group experienced greater improve-
ments in GAF and signiﬁcantly greater improvements in CGI
(GAF: early = +14.1, late = +12.5, p = 0.30; CGI: early = −1.04,
late = −0.76, p = 0.017). CONCLUSION: This interim analysis
suggests that treatment with RLAI result in better outcomes in
patients with schizophrenia who have been diagnosed for less
than ﬁve-years than those diagnosed for ﬁve or more years.
PMH42
IMPACT OF ALTERNATIVE CENSORING SPECIFICATIONS ON
TIME-TO-EVENT ANALYSES COMPARING ALTERNATIVE
MEDICATIONS
McCombs JS, Stafkey-Mailey DR
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: Cox proportional hazards models comparing
patient outcomes achieved across alternative drug therapies may
be sensitivity to alternative speciﬁcations for censoring of the
data prior to an event. Three criteria are used in drug studies:
duration of therapy; time to a change in therapy; and end of
available data. METHODS: California Medicaid data for
1994–2003 were used to identify 165,013 episodes of antipsy-
chotic drug therapy initiated during CY2000–2002 by patients
with schizophrenia. Cox models were estimated separately for
acute or a psychiatric hospital admissions controlling for patient
demographics, diagnostic proﬁle, prescription drug proﬁle and
prior health care use. Four types of treatment episodes were
deﬁned based on discontinuation of therapy: patients restarting
or switching drugs after a break in therapy >15 days and patients
switching or augmenting a pre-existing antipsychotic regimen
with no break in treatment. Clozapine or ziprasidone episodes
were excluded due to small sample size. Patients initiating treat-
ment using a typical antipsychotic (TAP) were combined into a
single comparison group. RESULTS: Patients using atypical
antipsychotics achieved longer duration of therapy than TAP
patients for all episode types, creating a longer period of risk
exposure for an event in Cox models that censor data based on
duration of therapy. The Cox models for all episode types com-
bined did ﬁnd that the hazard ratios for all three atypical antipsy-
chotics were reduced relative to TAP when duration of therapy
was dropped as a censoring criterion. However, changes in the
estimated hazard ratios were small and the results from separate
analyses by episode type were not always consistent with the
aggregate model results. Patients switching therapies were con-
sistently found to be at higher risk for hospitalization than
patients restarting a drug used in their previous treatment
attempt. CONCLUSION: Cox hazard ratios are sensitive to cen-
soring speciﬁcations based on duration of therapy.
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SWITCHING OF ANTIPSYCHOTICS AMONG STABLE AND
UNSTABLE SCHIZOPHRENIA PATIENTS
Zhu B,Ascher-Svanum H, Johnstone B, Faries D
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: To assess switching of atypical and typical
antipsychotics among stable and unstable patients and the rela-
tionship between switching and hospitalization. METHODS: We
used data from the ﬁrst year of a large (N = 2327), 3-year non-
interventional observational study of schizophrenia patients in
the U.S, conducted between 7/1997 and 9/2003. Participants
with at least one prescription for any antipsychotic were included
in this analysis. Participants were deﬁned as “stable” if they had
PANSS total scores below 70 at enrollment and no psychiatric
hospitalization, psychiatric emergency services, suicide attempt,
or arrest in the 1–6 months prior to enrollment. All other par-
ticipants were deemed “unstable.” Systematic medical record
abstraction provided antipsychotic prescription information.
The stable and unstable patient groups were compared on
antipsychotic switching rates (switch from the antipsychotic used
at enrollment) and on antipsychotic augmentation. Group com-
parisons were performed using t-tests for continuous variables
and Chi-square tests for categorical variables. RESULTS: Of
2158 participants, 59.6% were deemed unstable and 40.4%
were considered stable. Unstable patients were more likely to
experience switching and augmentation of antipsychotics.
Typical antipsychotics were more likely to be used as augmen-
tors (58.7%, p < 0.001), whereas atypical antipsychotics, espe-
cially olanzapine, were more likely the medications to be
switched to (61.9%, p < 0.001). A signiﬁcantly higher propor-
tion of switchers (44.6%) than non-switchers (17.9%, p < 0.001)
were hospitalized for psychiatric purposes during the 1-year
observation period. Among switchers who were hospitalized at
any time during the 1-year period, 52.4% switched medication
during hospitalization, 29.8% switched prior to hospitalization,
and 17.8% switched post hospitalization. CONCLUSION:
Switching of antipsychotics appears to be signiﬁcantly associated
with unstable, more severe illness proﬁle and with psychiatric
hospitalizations. Atypical antipsychotics are more likely the med-
ications to be switched to. Finding an effective treatment option
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that stabilizes the disease and reduces hospitalizations will help
patients and payers as well.
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THE PREDICTIVE VALIDITY OF DIFFERENT ADHERENCE
MEASURES USING ADMINISTRATIVE CLAIMS DATA
Karve SJ, Martin BC
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: To determine the predictive validity of eight dif-
ferent adherence measures by studying the variability explained
between each measure and two outcome measures: hospitaliza-
tion episodes and total non-pharmacy cost. METHODS: This
study was a retrospective analysis of the Arkansas Medicaid
administrative claims data. Schizophrenia (ICD-9-CM = 295.**)
patients were identiﬁed in the recruitment period July 2000
through April 2004. Patients had to be >18 years old, have pre-
scription beneﬁts, and continuously eligible for 6 months prior
and 24 months after their ﬁrst antipsychotic prescription.
Persons taking two different antipsychotic drug products simul-
taneously were excluded. Medication Possession Ratio (MPR),
Proportion Of days Covered (PDC), Medication Possession
Ratio, modiﬁed (MPRm), Reﬁll Compliance Rate (RCR), Com-
pliance Ratio (CR), Continuous Measure of Medication Gaps
(CMG), Days Between Fills Adherence Rate (DBR), and Con-
tinuous, Single Interval Measure of Medication Acquisition
(CSA) were computed and modeled to predict hospitalizations
and non-pharmacy costs. RESULTS: A total of 3971 patients
with a mean age 46.5 years, 54% were female, 55% were white,
and 38% were black. The one-year adherence rates were numer-
ically similar for MPR (0.74 SD = 0.31) and PDC (0.72, SD =
0.29). Other measures such as MPRm (82.21%, SD = 27.27),
RCR (97.20% SD = 115.05), CR (81.39% SD = 64.18) DBR
(97.20% SD = 115.05) and CSA (0.95 SD = 0.79) had higher
adherence values. The partial R-squares of the multivariate
regression models will be reported. CONCLUSION: There is
considerable variability in rates of adherence among the 8 mea-
sures of adherence. MPR and PDC which used the entire study
period as the denominator had the most conservative adherence
values. In contrast MPRm, PDC, RCR, CR, DBR which only
consider the time between ﬁrst and last prescription ﬁll dates esti-
mate higher levels of adherence.
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SOCIODEMOGRAPHIC AND CLINICAL CORRELATES OF
UTILITY SCORES IN ALZHEIMERS DISEASE
Rosenheck RA1, Miller EA2, Schneider L3, Zbrozek A4
1Yale Medical School, West Haven, CT, CT, USA, 2Brown University,
Providence, RI, USA, 3University of Southern California Keck School
of Medicine, Los Angeles, CA, USA, 4Wyeth Research, Philadelphia,
PA, USA
OBJECTIVES: The pharmaco-economic evaluation of treatment
for Alzheimer’s Disease (AD) has relied on general measures of
utilities that have been validated in general populations. There
has been little study of the relationship between disease speciﬁc
measures of health status, functional capacity and/or quality of
life in AD and measures of Quality Adjusted Life Years (QALYs),
the outcome of primary interest in pharmaco-economic assess-
ments. METHODS: Follow-up data were obtained from care-
giver proxy raters at 3, 6, and 9 months concerning 421 patients
with early stage Alzheimers Disease, living with at least one care-
giver in a non-institutional setting, who participated in the
CATIE AD trial of antipsychotic medication for psychosis or
aggression due to AD. Multiple regression models were used to
examine the relationship between change in the Health Utilities
Index (HUI)—Mark III, and a broad range of socio-demographic
characteristics, psychiatric symptoms, cognitive performance,
activities of daily living, and AD-related quality of life—to deter-
mine the measures that were most strongly related to QALYs 
and the power of clinical measures to predict utility scores.
RESULTS: Analysis of correlates of change in utilities scores
from baseline showed weak bivariate, and for the most part,
non-signiﬁcant multivariate relationships between change in
health utility scores and measures of socio-demographic charac-
teristics, psychiatric symptoms, and cognitive performance.
However, there were highly signiﬁcant associations between
decreases in health utilities and change two scales: the AD Coop-
erative Study Scale for Activities of Daily Living (ADCS-ADL)
and AD-Related Quality of Life (ADRQoL) (both p < 0.001).
The total R-squared was 17%. CONCLUSION: Only weak rela-
tionships were found between changes in a standard measure of
health utilities and socio-demographic and clinical indicators.
The presence of signiﬁcant cognitive impairment and the need to
rely on proxy raters may limit the validity of utility measurement
in AD.
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NOVEL USE OF A TELEPHONE BASED INTERACTIVE VOICE
RESPONSE SYSTEM TO IMPROVE DATA COLLECTION
Pierce J,Wenzel K
ClinPhone, East Windsor, NJ, USA
OBJECTIVES: To investigate whether electronic memory aids
and IVR verbal numeric scales improve the quality of data col-
lection methods. To evaluate whether perceptions of clinical
change reported directly by the patient is enhanced by the use of
a novel telephone based interactive voice response system.
METHODS: A total of 137 patients from a multi-site, double-
blind, placebo controlled study were administered the IVR 
PGI-I and the Memory Enhanced Retrospective Evaluation 
of Treatment (MERET) over a 4-week period. Effect sizes using
these approaches were determined and compared to determine
any differences. In addition, we investigated whether dosage level
predicted a more rapid onset of action. RESULTS: At 2 and 4
weeks the point estimates for both IVR PGI-I and MERET were
2.68 and 3.24 (p = 0.035) and 2.5 and 3.21 (p = 0.015), respec-
tively. Overall, the effect size for the PGI-I was 0.526 compared
to 0.612 for MERET. For the subjects in the higher dose group,
there were signiﬁcant improvements reported by the patient at 1
day for shoulder (p = 0.008) and back pain (p = 0.01). Signiﬁ-
cant differences were also found at day 3 for pain while awake
(p = 0.03), day 5 for Global emotional improvement (p = 0.03),
and day 7 and Global physical improvement (p = 0.04) at day
7. No other signiﬁcant differences were found. CONCLUSION:
The use of an electronic memory aid produced a 16.3% larger
drug-placebo treatment effect size compared to the standard
PGI-I. MERET ratings increased the patients’ perception on the
effectiveness of active drug treatment with minimal inﬂuence of
the placebo effect. In this study, the higher dose had an earlier
onset of efﬁcacy for both physical and emotional symptoms. The
daily IVR reporting of this data allowed detection of a rapid
onset of action.
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THE EFFECTS OF PATIENT TYPE ON PHYSICAL AND MENTAL
HEALTH OF CAREGIVERS IN FRANCE, GERMANY, ITALY,
SPAIN AND THE UNITED KINGDOM
Kannan H, Bolge SC
Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVES: To assess the effects of caring for adult patients
with chronic conditions on the physical and mental health of
caregivers. METHODS: This analysis was based on data from
